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A B S T R A C T
Objective: The aim of this study was to investigate whether smokers with incidental ﬁndings of interstitial lung
abnormalities have an increased mortality during long-term follow-up, and review the contributing causes of
death.
Methods: Baseline CT scans of 1990 participants from the Danish Lung Cancer Screening Trial were qualitatively
assessed for predeﬁned interstitial lung abnormalities of any severity. Inclusion criteria for this lung cancer
screening trial included current or former smoking,> 20 pack-years, and age 50–70 years. Patients were fol-
lowed up for up to 12 years.
Results: We found interstitial lung abnormalities in 332 participants (16.7%). Interstitial lung abnormalities
were associated with increased all-cause mortality in the full cohort (HR: 2.0, 95% CI: 1.4–2.7, P < 0.001) and
in lung cancer-free participants (HR: 1.6, 95% CI: 1.1–2.4, P=0.007). The ﬁndings were associated with death
from lung cancer (HR: 3.2, 95% CI: 1.7–6.2, P < 0.001) and non-pulmonary malignancies (HR: 2.1, 95% CI:
1.1–4.0, P=0.02). Participants with ﬁbrotic and non-ﬁbrotic interstitial lung abnormalities had similar sur-
vival.
Conclusion: Interstitial lung abnormalities were common in this lung cancer screening population of relatively
healthy smokers and were associated with mortality regardless of the interstitial morphological phenotype. The
increased mortality was partly due to an association with lung cancer and non-pulmonary malignancies.
1. Introduction
Interstitial lung abnormalities (ILA) are areas of increased lung
density visible on computed tomography (CT) of the lung in individuals
with no known interstitial lung disease. These radiological ﬁndings,
including ground-glass opacities, reticulation, nodular patterns, and
honeycombing, are also present in several interstitial lung diseases,
such as idiopathic pulmonary ﬁbrosis (IPF) and can precede the onset of
symptoms by several years [1,2]. However, not all ILA develop into
symptomatic lung disease and the clinical implications of ILA are still
the subject of ongoing research.
ILA have been detected in smokers and participants of lung cancer
screening trials, and ﬁbrotic ILA have been shown to progress radi-
ologically within 2–4 years of follow-up [3–7]. The radiological ﬁnd-
ings of ILA are associated with measurable changes in lung volume, gas
exchange, and exercise capacity [5,7,8].
In previous reports, ILA have been found to be associated with
greater risk of all-cause mortality [9,10], but the cause of this asso-
ciation is not entirely clear. A tempting explanation could be the de-
velopment of some ILA into clinical interstitial lung disease or lung
cancer, but these possible scenarios remain to be proven.
The aim of this study was to investigate whether healthy smokers
with incidental ﬁndings of interstitial lung abnormalities have an in-
creased mortality during long-term follow-up, and classify the con-
tributing causes of death.
https://doi.org/10.1016/j.rmed.2018.02.001
Received 16 November 2017; Received in revised form 30 January 2018; Accepted 1 February 2018
∗ Corresponding author. Department of Respiratory Medicine, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark.
E-mail address: nils.hoyer.01@regionh.dk (N. Hoyer).
Respiratory Medicine 136 (2018) 77–82
Available online 03 February 2018
0954-6111/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
2. Methods
2.1. Study population
All participants in the intervention arm of the Danish Lung Cancer
Screening Trial (DLCST) were eligible for this registry-based follow-up
study. Details of the methods of the DLCST, including criteria of elig-
ibility, have been published previously and are brieﬂy described below
[11]. The DLCST was a 4- year, 5-round prospective randomized con-
trolled screening trial. From 2004 to 2006, 4104 men and women aged
50–70 years with a smoking history of at least 20 pack-years were in-
cluded in the study. Former smokers had to have quit after the age of 50
years and within the previous 10 years. Baseline FEV1 had to be≥ 30%
of the predicted value and participants had to be able to climb two
ﬂights of stairs (total of 36 steps) without pausing. Exclusion criteria
were weight> 130 kg, history of cancer diagnosis and treatment, lung
tuberculosis, shortened life expectancy<10 years, and chest CT
screening during the past year for any reason. Participants with sus-
pected malignant ﬁndings were immediately referred for further in-
vestigations. However, participants with interstitial ﬁndings were not
systematically followed up for either diagnosis or treatment. The DLCST
was approved by the Ethics Committee of Copenhagen County and fully
funded by the Danish Ministry of Interior and Health. Approval of data
management in the trial was obtained from the Danish Data Protection
Agency. All participants provided written informed consent and the
study was conducted according to the principles of the Declaration of
Helsinki.
In the present follow-up study, participants were included in the
survival analysis provided they were randomized to the screening arm
and had an evaluated CT scan available (n=1990). Seventy partici-
pants developed lung cancer during follow-up. Survival analysis was
performed both with the entire cohort and with lung cancer free par-
ticipants (n=1920), to unmask possible confounding by this co-mor-
bidity (Fig. 1). All participants were included in the cause of death
analysis, to ensure completeness of data.
2.2. Imaging and image review
Baseline scans from the DLCST were used for this follow-up study.
Details about the imaging procedure have previously been published
[12]. The screening group was examined annually, using a multi-slice
CT system (16 rows Philips Mx 8000, Philips Medical Systems). Scans
were performed supine at full inspiration with a low-dose technique
(120 kV and 40mAs). Two sets of images were then reconstructed: thick
(3mm) and thin (1mm) slices using soft and hard algorithms (kernel C
and D), respectively. Visual assessment was performed on thin slices,
kernel D. Two diﬀerent sets of all scans were created in random order,
and each set was evaluated by one of two observers (MW and LT) that
were blinded to person identiﬁcation and scan dates. Interstitial lung
abnormalities were registered by both readers as either absent or pre-
sent. If present, ILA were further categorized as centrilobular, pleural,
or paraseptal nodules, ground-glass attenuation, reticulation and/or
honeycombing. The interobserver agreement in the detection of ILA
was fair to substantial and has previously been published in greater
detail [13]. For categorical data such as the diﬀerent ILA, we used the
results of a single observer (the observer who reported abnormal
ﬁndings most frequently [MW]). For comparison, we repeated our
analyses using results of the second observer (LT), which lead to the
same conclusions in all analyses, unless speciﬁcally stated.
2.3. Registries
Participants were followed up via the Danish Civil Registry system,
which contains the vital information of the entire Danish population.
Censoring events were emigration (n=18), reported missing (n=2),
or end of follow-up (December 2016), whichever occurred ﬁrst. Death
causes were acquired from the Danish Cause of Death Registry, which at
the time was updated until December 2015. Death causes were classi-
ﬁed into ﬁve diﬀerent groups based on ICD10 codes: cardiovascular
disease (ICD10 codes I00-I99), respiratory disease (ICD10 codes J00-
J99), lung cancer (ICD10 code C34), non-pulmonary malignancies
(ICD10 codes C00-C99, excluding C34), and other causes of death (all
remaining ICD10 codes).
2.4. Data analysis
Analysis of baseline characteristics and causes of death in the cohort
was performed with an unpaired t-test or Fisher's exact test for con-
tinuous and categorical variables, respectively.
Survival analysis was performed with Cox regression models ad-
justing for age, sex, smoking status (active or former), pack-years, BMI,
and FEV1. Continuous covariates were included after checking for lin-
earity in the Cox model. Linearity was not justiﬁed for BMI as a con-
tinuous variable and it was therefore included as an unordered cate-
gorical variable with the categories underweight (BMI < 18.5), normal
(BMI 18.5–25) and overweight (BMI > 25). All models were assessed
for proportional hazards and no violations of this assumption were
found. Biologically plausible interaction terms, such as interaction be-
tween sex and FEV1, were tested for, and no signiﬁcant interactions
were found. To improve adjustment for age, we also performed a Cox
regression replacing time-on-study with age as the timescale, which is
recommended for epidemiological data where age is expected to be a
substantial confounder [14]. We also repeated the Cox regression
stratiﬁed according to age groups with ﬁve-year intervals. Survival
analysis was repeated after dividing all ILA into ﬁbrotic (reticulation
and honeycombing) or exclusively non-ﬁbrotic (ground glass opacities
and nodular pattern) as the rate of radiologic progression has been
shown to be dependent on this distinction [4]. The cause of death
Fig. 1. Generation of the study population for this follow-up study from the intervention
arm of the Danish Lung Cancer Screening Trial (DLCST). All participants with chest CT
scan data were included in the primary analysis and all participants that remained lung
cancer free during follow-up were included in the secondary analysis. ILA: interstitial
lung abnormalities.
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analysis was performed with a competing risk multiple Cox regression
with all other death causes (including unknown death causes) treated as
censoring events.
All P-values are two-sided and a P-value< 0.05 was considered
signiﬁcant. All statistical analyses were performed with the statistical
package R (version 3.3.3).
3. Results
3.1. Prevalence of ILA
Interstitial lung abnormalities were found in the baseline scans of
332 participants (16.7%). Participants with ILA were generally older,
had more airway obstruction and tended to have been exposed to more
pack-years, compared to participants without ILA (Table 1, Fig. 2).
When limiting the analysis to participants who remained lung cancer
free during follow-up, ILA were found in 298 participants (15.5%)
(Table 1).
3.2. Association of ILA with mortality
In multiple Cox regression models, a ﬁnding of ILA at baseline was
associated with an increase in all-cause mortality (HR: 2.0, 95% CI:
1.4–2.7, P < 0.001) over a period of up to twelve years of follow-up
(Table 2). This increase in mortality was still signiﬁcant when excluding
participants that developed lung cancer during follow-up (HR: 1.6, 95%
CI: 1.1–2.4, P=0.007) (Table 2).
3.3. Age and ILA
Older participants in our cohort were more likely to have ILA
(Table 1, Fig. 2). However, repeating the Cox regression analysis with
age as timescale, rather than time-on-study, did not alter the eﬀect size
or signiﬁcance in either the full cohort (HR: 2.0, 95% CI: 1.5–2.7,
P < 0.001) or in lung cancer-free participants (HR: 1.7, 95% CI:
1.2–2.4, P=0.006) (Fig. 3).
After dividing participants into age groups in 5-year intervals based
on age at the time of CT scan, the association of ILA with mortality
remained signiﬁcant in the two largest age groups, containing partici-
pants aged 55–60 years (HR: 2.3, 95% CI: 1.2–4.1, P=0.003) and
60–65 years (HR: 2.1, 95% CI: 1.2–3.5, P=0.005) in multiple Cox
regression analyses. The other age groups contained fewer participants
and we found no signiﬁcant association between ILA and mortality
within these groups.
3.4. ILA morphology and mortality
To determine if the increased mortality was caused by a speciﬁc
radiological ﬁnding, we investigated the diﬀerent ILA morphologies
(ground-glass opacities, nodular pattern, reticulation, and honey-
combing) separately. All investigated ﬁndings were associated with
mortality, both in the entire cohort and when limiting the analysis to
participants that remained lung cancer-free during follow-up (Table 2).
The most detrimental ﬁnding was honeycombing, both in the full co-
hort (HR: 6.7, 95% CI: 2.9–15.4, P < 0.001) and in lung cancer-free
participants (HR: 4.2, 95% CI: 1.0–17.2, P=0.04) (Table 2).
When dividing the ﬁndings into ﬁbrotic ILA (reticulation and hon-
eycombing) and exclusively non-ﬁbrotic ILA (nodular pattern and
ground-glass opacities), multiple Cox regression showed no diﬀerence
in survival between the two groups (P=0.8) (Fig. 4).
3.5. Causes of death
To further elucidate the increased mortality associated with ILA, we
investigated the registered cause of death for all participants. ILA
ﬁndings were associated with increased deaths from lung cancer (HR:
3.2, 95% CI: 1.7–6.2, P < 0.001) and non-pulmonary malignancies
(HR: 2.1, 95% CI: 1.1–4.0, P=0.02) in competing risk Cox regression
models (Table 3). Deaths attributable to cardiovascular and respiratory
disease in this cohort seemed independent of ILA (Table 3). Repeating
the analyses using scores from a diﬀerent reader (LT) resulted in the
same conclusion for lung cancer, but did not show an association
Table 1
Baseline characteristics of participants with or without a baseline CT ﬁnding of ILA. SD: standard deviation, BMI: body mass index, FEV1: forced expiratory volume in 1 second, FVC:
forced vital capacity.
All participants Participants without lung cancer
ILA (n= 332) No ILA (n= 1658) P-value ILA (n= 298) No ILA (n= 1622) P-value
Age mean (SD), years 59.7 (5.0) 57.6 (4.7) < 0.001 59.5 (4.9) 57.6 (4.7) < 0.001
Female, n (%) 136 (41) 742 (45) 0.2 119 (40) 725 (45) 0.1
BMI, mean (SD) 24.9 (4.0) 25.3 (3.8) 0.06 24.8 (3.9) 25.3 (3.8) 0.07
Current/former smokers, n (%) 256/76 (77/23) 1243/415 (74/26) 0.4 229/69 (77/23) 1213/409 (75/25) 0.5
Pack-years, mean (SD) 37.5 (13.4) 36.2 (13.4) 0.1 37.5 (13.6) 36.0 (13.4) 0.08
FEV1 l, mean (SD) 2.75 (0.76) 2.91 (0.75) < 0.001 2.80 (0.76) 2.92 (0.75) 0.01
FEV1% predicted, mean (SD) 87.9 (18.6) 92.4 (16.3) < 0.001 89.2 (18.1) 92.6 (16.2) 0.002
FVC l, mean (SD) 4.03 (1.0) 4.13 (0.99) 0.1 4.08 (1.00) 4.14 (0.99) 0.3
FVC % predicted, mean (SD) 99.5 (17.7) 101.7 (15.3) 0.04 100.3 (17.3) 101.8 (15.2) 0.2
FEV1/FVC, mean (SD) 0.68 (0.09) 0.71 (0.08) < 0.001 0.69 (0.09) 0.71 (0.08) <0.001
Follow-up time median, years (IQR) 11.22 (10.77–11.75) 11.29 (11.03–11.75) < 0.001 11.24 (10.93–11.73) 11.30 (11.04–11.75) 0.03
0%
10%
20%
30%
40%
50%
50−54 55−59 60−64 65−70
Age (years)
Fig. 2. Proportion of participants with a ﬁnding of ILA at baseline divided into four age
groups. The plot is based on all participants, including those who developed lung cancer
during follow-up.
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between ILA and non-pulmonary malignancies (HR: 1.1, 95% CI:
0.5–2.2, P=0.87).
4. Discussion
Interstitial lung abnormalities were a common ﬁnding in the Danish
Lung Cancer Screening Trial population and were associated with in-
creased mortality, regardless of the underlying morphological pheno-
type. A ﬁnding of ILA in this group of relatively healthy smokers was a
risk factor for death from lung cancer and possibly non-pulmonary
malignancies.
The prevalence of ILA (16.7%) in this cohort was similar to previous
reports of lung cancer screening populations, which report a prevalence
of 9.7%–22.8% [3,4]. Possible explanations for this high prevalence
include the use of full chest CT scans and the participants' high age and
tobacco exposure. We did not classify any ﬁndings as indeterminate,
but included all ILA in our analysis, regardless of the intensity and
overall radiological pattern, which may have contributed to the high
prevalence [3,4,7,9].
Interestingly, a ﬁnding of ILA was not dependent on smoking status
at baseline, although there was a non-signiﬁcant trend towards more
frequent ILA in participants with more pack-years. This is in contrast to
previous ﬁndings from lung cancer screening and general population
cohorts [4,6,9], but similar to some cohorts of patients with signiﬁcant
smoking exposure and chronic obstructive pulmonary disease (COPD)
[9]. A possible explanation for this discrepancy could be a non-linear
relationship between smoking and ILA, where additional exposure be-
yond 20 pack-years (the inclusion criteria for our cohort) has less im-
pact on the presence of ILA compared to less extreme exposure.
Table 2
Prevalence and adjusted hazard ratio of mortality for diﬀerent ILA in the entire cohort or lung cancer-free participants, respectively. Multiple Cox regression models were adjusted for age,
sex, smoking status, pack-years, FEV1, and BMI. There can be multiple types of ILA in one scan. HR: hazard ratio, CI: conﬁdence interval, BMI: body mass index, FEV1: forced expiratory
volume in 1 second.
All participants Participants without lung cancer
n (%) HR (95% CI) P-value n (%) HR (95% CI) P-value
Any ILA 332 (16.7) 2.0 (1.4–2.7) < 0.001 298 (15.5) 1.6 (1.1–2.4) 0.007
Ground glass 115 (5.8) 2.3 (1.5–3.4) < 0.001 99 (5.2) 1.8 (1.1–3.0) 0.03
Nodular pattern 155 (7.8) 2.2 (1.5–3.2) < 0.001 141 (7.3) 2.1 (1.4–3.3) <0.001
Reticulation 162 (8.1) 1.8 (1.2–2.6) 0.004 144 (7.5) 1.6 (1.0–2.6) 0.03
Honeycombing 12 (0.6) 6.7 (2.9–15.4) < 0.001 8 (0.4) 4.2 (1.0–17.2) 0.04
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Fig. 3. Cumulative all-cause mortality in participants stratiﬁed according to ILA at baseline. The mortality curves use age as a timescale and represent the full cohort with all participants
(A) or the participants who remained lung cancer free during follow-up (B). The risk set varies because the data is both left truncated and right censored. For curves with time-on-study as
timescale, see the online supplemental data.
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Fig. 4. Cumulative all-cause mortality in participants stratiﬁed according to ILA at
baseline. Participants with any type of ﬁbrotic ILA (reticulation and honeycombing) were
compared to exclusively non-ﬁbrotic ILA (nodular pattern or ground-glass opacities) or no
ILA. The mortality curves use age as the timescale and represent the full cohort with all
participants. The risk set varies because the data is both left truncated and right censored.
For curves with time-on-study as timescale, see the online supplemental data.
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We show for the ﬁrst time, that several ILA morphologies are as-
sociated with mortality. This suggests that no single radiological ﬁnding
and thus, probably no single disease entity, is exclusively responsible
for the increased mortality associated with ILA. The rare ﬁnding of
honeycombing was associated with the greatest increase in mortality,
which can be explained by honeycombing representing end-stage ﬁ-
brotic lung disease. The strong association with the exclusively non-
ﬁbrotic ﬁndings (i.e. ground-glass opacities and nodular patterns in the
absence of any ﬁbrosis) over a 12-year follow-up period was surprising
because these have been shown to be more stable compared with ﬁ-
brotic ILA [4]. One possible explanation for this ﬁnding is that non-
ﬁbrotic ILA represent premalignant changes, explaining the increased
incidence of lung cancer, or pro-inﬂammatory conditions impacting
mortality due to other cancers. However, it is also possible that ILA is
merely a surrogate marker, rather than a contributor to the poor
prognosis.
We found a clear relationship between age and the presence of ILA,
requiring rigorous statistical adjustment to disprove that the increased
mortality in participants with ILA is simply due to their higher age
alone. Using age as a timescale in survival models has been shown to be
superior in adjusting for the confounding eﬀects of age in epidemiologic
studies [14]. However, even after this adjustment, ILA were associated
with mortality in our cohort. Further stratiﬁcation into 5-year age
groups did not alter the association either. The signiﬁcance of ILA, even
after rigorous adjustment for age as a confounding variable, suggests
that the association with mortality can be only partially explained by
the older age of the participants with ILA.
We found ILA to be associated with death from both lung cancer and
non-pulmonary malignancies, which is consistent with previous results
showing that smokers with lung cancer often have histopathological
ﬁbrosis in their lungs and that lung cancer is strongly associated with
ILA [15,16]. Our results show that ILA ﬁndings during lung cancer
screening should not be ignored, as they are a risk factor for later death
from clinical lung cancer. Thus, an ILA ﬁnding should be considered as
a selection criterion in a targeted lung cancer screening program.
However, the exclusion of all participants that developed lung cancer
did not remove the association between ILA and mortality. We there-
fore suggest that the increased mortality in this population is not due to
the increase in lung cancer alone. Another contributing factor was the
less pronounced association between ILA and death from non-pul-
monary malignancies. A comparable association between radiological
lung ﬁndings and non-pulmonary malignancies has been shown for
emphysema [17]. This association could be due to shared genetic or
environmental risk factors between ILA and non-pulmonary malig-
nancies including extra-pulmonary eﬀects of smoking. Previously re-
ported increased odds of death due to respiratory causes, including lung
ﬁbrosis, in a general population with ILA could not be replicated in this
lung cancer screening population, presumably due to the low number of
respiratory deaths including deaths due to interstitial lung disease [9].
The low frequency of respiratory deaths (other than lung cancer) in this
cohort of heavy smokers was surprising but could be explained by re-
spiratory disease being considered a contributing cause, rather than the
direct cause of death in some participants. Considering death causes
alone may underestimate the prevalence of respiratory disease in
smokers with ILA, which underscores the need for further research of
the morbidity related to ILA in this group, including the development of
clinically manifest interstitial lung diseases.
4.1. Limitations
Our study has several limitations that need to be considered.
We excluded 62 participants without CT scan data. These were
participants who died or dropped out within the ﬁrst year after inclu-
sion.
Using results from only one reader is a limitation, which we tried to
address in the following ways. Repeating analyses with the ﬁndings
from a second reader yielded comparable results in all instances except
one. In contrast to previous reports, we did not code any ﬁndings as
‘indeterminate’, but limited the analysis to a simple dichotomous
variable of ILA or no ILA. This potentially weakened our conclusions by
including less severe ﬁndings in the ‘exposed’ group. However, any cut-
oﬀ between diﬀerent grades of severity would be arbitrary and not
easily transferred to clinical practice, which could make it diﬃcult to
interpret. In addition, we relied on qualitative descriptors of ILA in
contrast to quantitative measures. This reduces the repeatability of our
ﬁndings and reduces the data quality. However, our approach is similar
to the use of imaging in clinical practice today and several comparable
studies [3,5,9].
Data on the participant's subsequent clinical diagnosis and treat-
ment for interstitial lung disease were not available for analysis. It
could be expected that treatment aﬀects the association between ILA
and mortality and this information should ideally be included in the
statistical analysis.
Low diﬀusion capacity is associated with increased mortality in
interstitial lung disease and would have been relevant to include in the
analysis, but data on diﬀusion capacity are not available in the DLCST
[18]. Consequently, we are unable to assess the eﬀect of the ILA
changes that is mediated through low diﬀusion.
The cause of death data was based on data from death certiﬁcates
with all the well-known uncertainties and inaccuracies of this approach.
However, cancer diagnoses were histologically veriﬁed.
Our analysis was based on ﬁndings from low-dose CT scans, rather
than high resolution CT (HRCT), which is the standard imaging test in
the diagnosis of interstitial lung disease. Although low-dose CT can give
false positive ILA ﬁndings [5], this limitation is inherent to lung cancer
screening, which is performed by low-dose CT to reduce radiation ex-
posure. Consequently, our results demonstrate the ILA ﬁndings that
would be expected from lung cancer screening.
5. Conclusion
Interstitial lung abnormalities were common in the Danish Lung
Cancer Screening Trial population and were associated with increased
mortality, regardless of the interstitial morphological phenotype. The
increased mortality could be partly explained by increased age and
death due to both lung cancer and non-pulmonary malignancies. Our
ﬁndings have important implications for future lung cancer screening
programs.
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